DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has forty patent family members in thirty countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
Reyvow will be eligible for patent challenges on January 31, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 6, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for REYVOW
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||54|
|Drug Prices:||Drug price information for REYVOW|
|What excipients (inactive ingredients) are in REYVOW?||REYVOW excipients list|
|DailyMed Link:||REYVOW at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for REYVOW
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|Portugal||1492786||Get Started Free|
|European Patent Office||1492786||Get Started Free|
|Croatia||P20040883||Get Started Free|
|Taiwan||I263497||Get Started Free|
|Japan||4493345||Get Started Free|
|Egypt||25226||Get Started Free|
|South Korea||100985995||Get Started Free|
|>Country||>Patent Number||>Estimated Expiration|